Therapeutic efficacy of an anti-PD-L1 antibody based immunocytokine in a metastatic mouse model of colorectal cancer
详细信息 查看全文
- 作者：Xi Chena ; b ; 1 ; Jin Xub ; c ; 1 ; Qingcheng Guoa ; b ; 1 ; Lingfei Wanga ; b ; Yun Yangb ; g ; Huaizu Guob ; c ; Nana Guc ; Dapeng Zhangb ; c ; d ; Weizhu Qianb ; c ; f ; Sheng Houb ; c ; d ; Jing Lib ; c ; Jianxin Daib ; c ; d ; Yajun Guob ; d ; e ; f ; yguo_smmu@163.com" class="auth_mail" title="E-mail the corresponding author ; Hao Wanga ; b ; d ; hwang_smmu@163.com" class="auth_mail" title="E-mail the corresponding author
- 关键词：Immunocytokine ; Anti-PD-L1 ; IL-2 ; T cell activation ; Tumor inhibition ; Metastatic colorectal cancer
- 刊名：Biochemical and Biophysical Research Communications
- 出版年：2016
- 出版时间：11 November 2016
- 年：2016
- 卷：480
- 期：2
- 页码：160-165
- 全文大小：687 K
文摘
- •
A novel immunocytokine termed as BIPI was generated by fusing hIL-2 to the C-Term of atezolizumab.
- •
It was effective in stimulating T cell activation and could selectively localize to the tumor.
- •
Tumor regression and prolonged survival were observed in metastatic colorectal cancer mouse model.
- •
BIPI induced the IFN-γ secretion in the spleen of mice.
- •
BIPI has the potential to treat cancers with a low response to anti-PD-L1 antibody or IL-2 treatment.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |